Association Between the Extended tau Haplotype and Frontotemporal Dementia

Patrice Verpillat, MD; Agnès Camuzat, BS; Didier Hannequin, MD; Catherine Thomas-Anterion, MD; Michèle Puel, MD; Serge Belliard, MD; Bruno Dubois, MD; Mira Didic, MD; Bernard-François Michel, MD; Lucette Lacamblez, MD; Olivier Moreaud, MD; François Sellal, MD; Véronique Golfier, MD; Dominique Campion, MD, PhD; Françoise Clerget-Darpoux, PhD; Alexis Brice, MD

Background: Recent studies have shown an association between an extended tau haplotype (H1) that covers the entire human tau gene and progressive supranuclear palsy or, more inconsistently, other neurodegenerative disorders, such as corticobasal degeneration, Parkinson disease, Alzheimer disease, and frontotemporal dementia (FTD). In addition, disease-causing mutations in the tau gene on chromosome 17 have been detected in some families with autosomal dominant FTD and parkinsonism. In FTD, the pathological accumulation of the microtubule-associated protein tau suggests that the tau gene may be a genetic risk factor for this disorder.

Objective: To confirm or refute the association between the H1 haplotype or the H1H1 genotype of the tau gene and FTD.

Design: Case-control study.

Setting: Neurology departments of 12 French university hospitals.

Participants: One hundred unrelated patients with FTD and 79 controls.

Methods: Tau genotype (contiguous polymorphisms in exons 1, 7, and 13 and in intron 9 used to reconstruct the extended haplotypes H1 and H2). Clinical examination, psychometric testing, laboratory tests, computed tomography and magnetic resonance imaging, single-photon emission computed tomography, and electroencephalography for patients with FTD.

Results: The H1H1 genotype was significantly over-represented in patients with FTD compared with controls (62% vs 46%; \( P = .01 \), 1-sided; odds ratio adjusted for age and sex, 1.95). After stratification according to apolipoprotein E (APOE) genotype, we found a significant interaction between APOE and tau genotypes (\( P = .03 \)).

Conclusions: This study of the largest series of patients with FTD confirms the primary role of tau in FTD and establishes that the H1 haplotype of the tau gene and the E2 allele of APOE interact by an unknown mechanism that increases the risk of FTD.
**PARTICIPANTS AND METHODS**

**PARTICIPANTS**

After excluding all patients with autosomal dominant inheritance and mutation of tau (n = 6), our sample was composed of 100 unrelated patients with FTD (44% men) admitted consecutively to 12 hospitals in France in a 3-year period. All patients with FTD underwent a thorough clinical examination, including personal and familial medical history, neurologic and psychiatric investigations, psychometric testing (Mini-Mental State Examination, Mattis Dementia Rating Scale, Verbal Learning Test, and Frontal Assessment Battery), laboratory tests, computed tomography and magnetic resonance imaging, regional cerebral blood flow measurement (single-photon emission computed tomography), and electroencephalography. The diagnosis of FTD was established according to the Lund-Manchester clinical consensus criteria for FTD, revised in 1998. Age at onset was assessed by interviewing 1 or 2 next of kin and was defined as the age at which relevant symptoms first appeared according to the family (mean ± SD age at onset, 60.6 ± 9.3 years; range, 35-77 years). We identified 40 patients with at least 1 first- or second-degree relative with FTD but without autosomal dominant inheritance and mutation in the tau gene (30% of men; mean ± SD age at onset, 58.7 ± 9.0 years; range, 35-77 years).

Postmortem neuropathologic examination was performed in 3 patients. Blocks of frontal, temporal, parietal, and occipital cortex; amygdala; hippocampus; basal ganglia; thalamus; and cerebellum were stained with usual stains (hematoxylin-eosin and Bodian silver method associated with luxol fast blue). By gross examination, the frontal lobe was moderately to severely atrophic. All 3 patients showed degeneration of the cerebral cortex, which was severe in the frontal cortex, less severe in the temporal and parietal cortices, and generally absent in the occipital cortex. Degeneration was characterized by microvacuolation, considerable neuronal loss, and astrocytic gliosis, especially in layers I and II of the frontotemporal cortices and in the CA1 and subiculum regions. Swollen neurons, Pick bodies, Lewy bodies, neurofibrillary tangles, and senile plaques were absent. Therefore, frontal lobe atrophy lacking distinctive histologic characteristics or features was defined for each patient subjected to autopsy.

Patients with FTD were compared with 79 age-matched controls (30% men; mean ± SD age at examination, 60.0 ± 8.8 years; range, 38-77 years). Control subjects were the patients' spouses, healthy blood donors, or individuals living in nursing homes. All participants in this study were white and were living in France. Informed written consent was obtained from all participants, either directly or from the legal tutor.

**GENOTYPING AND HAPLOTYPE RECONSTRUCTION**

Polymorphisms of exons 1 (+5 A/G), 7 (528 G/A), and 13 (+34 T/C) were analyzed by polymerase chain reaction amplification, followed by digestion of the product with the diagnostic restriction enzyme. For polymorphism of exon tau protein is variably involved in the pathophysiology. The A0 allele of a dinucleotide polymorphism in intron 9 of the tau gene (included in the H1 haplotype) was first found to be associated with PSP. This association was replicated in different populations and extended to the entire H1 haplotype. The haplotype has also been found to be associated with CBD, Parkinson disease, and Alzheimer disease, but with inconsistent results.

Morris et al found no significant difference in the frequency of the A0 allele and the A0A0 genotype in 32 patients with FTD and in 75 control subjects. However, in 36 clinically ascertained patients with FTD, Ingelson et al recently found that H1 haplotype, in combination with the apolipoprotein E (APOE) ε4 allele, was a genetic risk factor for FTD.

The present study was initiated to determine whether an association between the H1 haplotype and FTD could be detected in a larger independent population of clinically ascertained patients with FTD and a different genetic background (French population) than in previous studies.

**RESULTS**

Assuming a 1-sided significance level of α = .05 and a power (1 - β) of 80%, the size of our sample (100 patients with FTD and 79 controls) was sufficient to detect an OR of at least 2.10 for carriers of the H1H1 genotype and of at least 1.85 for carriers of the H1 haplotype.

---

**Table 1. Haplotype and Genotype Frequencies in 100 Patients With FTD and 79 Controls**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Patients With FTD, No. (%)</th>
<th>Controls, No. (%)</th>
<th>1-Sided P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotypes</td>
<td>(n = 100)</td>
<td>(n = 79)</td>
<td></td>
</tr>
<tr>
<td>H1H1</td>
<td>62 (62)</td>
<td>36 (46)</td>
<td>.01</td>
</tr>
<tr>
<td>H1H2 + H2H2</td>
<td>38 (38)</td>
<td>43 (54)</td>
<td>.25</td>
</tr>
<tr>
<td>Alles</td>
<td>(n = 200)</td>
<td>(n = 158)</td>
<td>.057</td>
</tr>
<tr>
<td>H1</td>
<td>154 (77)</td>
<td>110 (70)</td>
<td></td>
</tr>
<tr>
<td>H2</td>
<td>46 (23)</td>
<td>48 (30)</td>
<td></td>
</tr>
</tbody>
</table>

*FTD indicates frontotemporal dementia.
Haplotype and genotype frequencies are presented in Table 1. No deviation from Hardy-Weinberg equilibrium was observed in the control group, for which the allele and genotype frequencies were similar to those reported in other European white populations.17,21,28 The distribution of the H1H1 genotype in patients with FTD and controls was significantly different (OR = 1.95; 95% CI, 1.18-3.22; P = .01) and borderline significant for the H1 haplotype frequency (OR, 4.6; 95% CI, 0.98-2.17; P = .057). The mean age at onset of symptoms was similar in the H1H1 group (60.5 ± 9.2 years) and in patients with other genotypes (61.5 ± 9.5 years) (P = .46). After stratification on the absence (FH−) or presence (FH+) of a familial history of FTD, the results were even more significant in the FH− group (H1H1 vs others: FH− group OR, 2.26; 95% CI, 1.25-4.11; P = .01; FH+ group OR, 1.46; 95% CI, 0.69-3.06; P = .16).

Because the H1 haplotype increased the risk of FTD in combination with APOE4,15 we next stratified our sample according to the presence or absence of an APOE4 allele in the genotype. No interaction was found in our sample, and no OR was significant (data not shown). However, because 2 previous independent studies suggested that the APOE2 allele is a risk factor for FTD and not APOE4, we then stratified our sample according to the presence or absence of an APOE2 allele in the genotype (Table 2). Multivariate logistic regression showed that the interaction between APOE and tau genotypes was significant (Pinteraction = −1.89; P = .03). Odds ratios calculated to take into account this interaction are presented in Table 3. The results remained significant, or borderline significant, even after Bonferroni correction for multiple tests.

The results of this case-control study, to our knowledge the largest performed to date in FTD, suggest that patients who are H1H1 homozygotes for the tau gene are at increased risk for developing FTD. The different results observed between patients with FH+ and those with FH− are probably owing to the difference in the sample size (40 patients with FH+ and 60 with FH−), and thus in the study power.

Table 2. Combined Analysis of tau Genotypes and APOE2 Alleles in 100 Patients With FTD and 79 Controls

<table>
<thead>
<tr>
<th>APOE Genotypes</th>
<th>tau Genotypes</th>
<th>Patients With FTD</th>
<th>Controls</th>
<th>Patients With FTD</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>H1H1</td>
<td>H1H2 + H2H2</td>
<td>7 (7)</td>
<td>3 (3)</td>
<td>10 (10)</td>
<td>4 (4)</td>
</tr>
<tr>
<td>H1- APOE-</td>
<td>E2+</td>
<td>55 (55)</td>
<td>29 (37)</td>
<td>28 (28)</td>
<td>39 (49)</td>
</tr>
<tr>
<td>E2-</td>
<td>62</td>
<td>36</td>
<td>38</td>
<td>43</td>
<td></td>
</tr>
</tbody>
</table>

*Data are given as number (percentage). APOE indicates apolipoprotein E; FTD, frontotemporal dementia; E2+, the presence of at least 1 E2 allele; and E2−, the absence of E2 allele.

**Comment**

The results of this case-control study, to our knowledge the largest performed to date in FTD, suggest that patients who are H1H1 homozygotes for the tau gene are at increased risk for developing FTD. The different results observed between patients with FH+ and those with FH− are probably owing to the difference in the sample size (40 patients with FH+ and 60 with FH−), and thus in the study power.
Previous studies have reported an association between this haplotype in the tau gene and PSP\textsuperscript{16,27} and CBD\textsuperscript{17,28} which are also characterized by neuronal accumulation of tau protein. It must be added that earlier studies\textsuperscript{10,24} of an association with the most common allele of the dinucleotide polymorphism (A0) in intron 9 of the tau gene reflect in fact the association with the broader haplotype. The A0 allele for this polymorphism is indeed included in the H1 haplotype.\textsuperscript{35} Two previous studies\textsuperscript{15,24} have analyzed this haplotype in patients with FTD, but the results were not significant. Because of the small size of the samples (36 and 32 patients with FTD, respectively), these studies probably did not have sufficient a priori statistical power to demonstrate a nonmajor effect of the H1 haplotype. Our study of 100 patients with FTD was sufficiently powerful to detect an effect (OR) of at least 2.10 for the H1H1 genotype and 1.85 for the H1 haplotype.

A possible confounding factor in our study could be “contamination” by patients with PSP or CBD. Therefore, we decided to use strict criteria for the diagnosis of FTD: (1) clinical diagnosis according to the Lund-Manchester clinical consensus criteria for FTD,\textsuperscript{2,39} (2) neuropsychologic confirmation of frontal lobe dysfunction, (3) frontal or frontotemporal atrophy on computed tomographic or magnetic resonance images, and (4) frontotemporal hyperperfusion on single-photon emission computed tomographic images. Furthermore, we used age-matched controls, and ORs were adjusted for age and sex to eliminate these possible confounding factors. So, although only a small proportion of the patients were examined neuropathologically (3%), which allowed confirmation of the diagnosis of FTD, misdiagnosis as PSP or CBD is unlikely given the criteria used to assess patients.

The recent findings of pathogenic mutations in the tau gene in 25% to 40% of patients with FTD and autosomal dominant inheritance\textsuperscript{10,13} and the association of an extended haplotype that covers the entire tau gene indicate that tau plays a primary role in FTD and also in other neurodegenerative disorders with altered tau profiles, such as PSP, CBD, and Parkinson disease. Although our findings clearly suggest that the tau gene is a genetic risk factor for FTD, the molecular mechanisms underlying this effect are not known yet. It is possible to speculate, however, that the H1 haplotype is associated with a different level of tau gene expression than the H2 haplotype. However, the biologically relevant polymorphisms that are responsible for the risk of the disease remain to be determined.

The interaction between the tau and APOE genes was significant. The logistic regression coefficient for the interaction term was negative, which explains why the estimated OR for carriers of both at-risk genotypes (carriers of the H1H1 tau genotype and of ≥1 APOE2 alleles) was lower than the OR estimated for only one of the at-risk genotypes. Therefore, the effects of these 2 risk factors do not seem to be synergistic but rather alternative: each at-risk genotype has an effect when individuals are carriers of one of them, but this effect disappears when individuals are carriers of both. The interaction found in our study (with APOE2) is different from that found by Ingelson et al\textsuperscript{15} (with APOE4). Divergent results have also been observed among studies of APOE in FTD. Indeed, several studies have suggested that APOE might be a risk factor in FTD, but APOE2 was associated with FTD in 2 studies\textsuperscript{45,46} and APOE4 in 2 other studies.\textsuperscript{42,44} The size of the case-control sample reported in the article by Ingelson et al\textsuperscript{15} (n = 36) could be another possible point of difference to explain why their results are different from ours. However, the molecular mechanisms for the interaction between tau and APOE in the pathway to tau physiopathology seen in FTD are still unknown and should be specified by molecular studies.

The fact that the H1 haplotype in the tau gene seems to be a risk factor for several neurodegenerative disorders with different clinical presentations, including FTD, suggests that these disorders share a common pathogenic mechanism that involves tau dysfunction. Further studies are needed to determine how the H1 haplotype in the tau gene affects the neurodegenerative processes to better understand the pathogenesis of such disorders.

Accepted for publication February 4, 2002.

From Institut National de la Santé et de la Recherche Médicale (INSERM) U535, Le Kremlin Bicêtre (Drs Verpillat and Clerget-Darpoux); the Department of Epidemiology and Biostatistics, University Hospital Bichat-Claude Bernard, Assistance Publique–Hôpitaux de Paris (AP-HP)/University Paris VII, Paris (Dr Verpillat); INSERM U289, University Hospital Salpêtrière, Paris (Drs Verpillat and Brice and Ms Camuzat); INSERM Equipe Propre Inserm (EPI) 9906, Rouen (Drs Hannequin and Campion); the Department of Neurology, University Hospital, Rouen (Dr Hannequin); the Department of Neurology, University Hospital, Saint-Etienne (Dr Thomas-Anterion); the Department of Neurology, University Hospital Purpan, Toulouse (Dr Puel); the Department of Neurology, University Hospital Pontchaillou, Rennes (Drs Belliard and Golffier); the Department of Neurology, University Hospital Salpêtrière, Paris (Dr Dubois); the Department of Neurology and Neuropsychology, University Hospital Timone, Marseille (Dr Didic); INSERM Equipe Mixte Inserm (EMI) U9926, Marseille (Dr Didic); the Department of Neurology, University Hospital Sainte-Marguerite, Marseille (Dr Michel); the Federation of Neurology Mazarin and the Department of Pharmacology (Dr Lacombiez) and the Department of Genetics, Cytogenetics and Embryology (Dr Brice), University Hospital Salpêtrière, Paris; the Department of Neurology, University Hospital, Grenoble (Dr Moreau); and the Department of Neurology, University Hospital, Strasbourg (Dr Sellal), France.

Author contributions: Study concept and design (Drs Verpillat, Hannequin, Thomas-Anterion, Dubois, Michel,
Campion, Clerger-Darpoux, and Brice); acquisition of data (Drs Verpillat, Hannequin, Thomas-Anterion, Puel, Belliard, Dubois, Didic, Michel, Lacambllez, Moreaud, Sellal, Gollier, Campion, and Brice and Ms Camuzat); analysis and interpretation of data (Drs Verpillat, Dubois, Campion, Clerger-Darpoux, and Brice); drafting of the manuscript (Drs Verpillat and Hannequin); critical revision of the manuscript for important intellectual content (Drs Hannequin, Thomas-Anterion, Puel, Belliard, Dubois, Didic, Michel, Lacambllez, Moreaud, Sellal, Gollier, Campion, Clerger-Darpoux, and Brice and Ms Camuzat); statistical expertise (Dr Verpillat); obtained funding (Drs Verpillat, Michel, Lacambllez, and Brice); administrative, technical, and material support (Drs Verpillat, Hannequin, Thomas-Anterion, Michel, Sellal, Campion, and Brice and Ms Camuzat); study supervision (Drs Verpillat, Hannequin, Dubois, Michel, Lacambllez, Campion, Clerger-Darpoux, and Brice).

This work was supported by a grant from the Fondation pour la Recherche Médicale and from INSERM, Paris. We thank Merle Ruberg, PhD, for her critical readings of the manuscript.

Corresponding author: Patrice Verpillat, MD, Département d’Épidémiologie, de Biostatistique, et de Recherche Clinique, Hôpital Bichat-Claude Bernard, 46 rue Henri Huchard, 75877 Paris CEDEX 18, France (e-mail: patrice.verpillat@bch.ap-hop-paris.fr).

REFERENCES